Efficacy and Safety of Cilostazol for the Indication of CSPS
Information source: Korea Otsuka Pharmaceutical Co.,Ltd.
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cerebral Infarction
Intervention: Cilostazol (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Korea Otsuka Pharmaceutical Co.,Ltd. Official(s) and/or principal investigator(s):
Bo Youn Seo, Study Director, Affiliation: Korea Otsuka Pharmaceutical Co.,Ltd.
Overall contact:
Bo Yeon Seo, Phone: 82-2-3465-5485, Email: byseo@otsuka.co.kr
Summary
This is a multicenter, open-label, prospective study of cilostazol use for prevention of
recurrence in patients with cerebral infarction.
Clinical Details
Official title: Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS
Study design: Natural History, Longitudinal, Case Control, Prospective Study
Detailed description:
This is a multicenter, open-label, prospective study of cilostazol use to prevention of
recurrence in patients with cerebral infarction.
Qualified patients will be treated with cilostazol by physician's assessment. This study
will be continued for 4 years. More than 600 patients for 4 years.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- a) Patient with an experience of cerebral infarction and having a purpose for
prevention of recurrence of cerebral infarction.
b) Age: more than 18 years of age
Exclusion Criteria:
- a) Unqualified patients judged by study investigator(s)
Locations and Contacts
Bo Yeon Seo, Phone: 82-2-3465-5485, Email: byseo@otsuka.co.kr
Asan Medical Center, Seoul, Korea, Republic of; Recruiting
S U Kwon, Professor, Phone: 82-3465-3500
Additional Information
Starting date: December 2003
Ending date: October 2007
Last updated: October 12, 2006
|
